Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Inside a life sciences fund: V-Bio Ventures

V-Bio Ventures, the new Belgian fund for life sciences startups, is currently being managed by Christina Takke and Willem Broekaert. They both hav…


Biotechs and subsidies - a fraught relationship

The ambition of any CEO heading a biotech start-up is to develop a new product and to reach patients quickly. However, drug development comes with…


Biotech through the eyes of a financial analyst

Ward Capoen studied biology and subsequently obtained a PhD in biotechnology at Ghent University. He worked as a postdoctoral fellow at the John I…

POPULAR TAGS

V-Bio Ventures announces the final closing of its first fund, raises over €75 million

Written by LVS on in the category news with the tags , .


After an initial closing in November 2015, V-Bio Ventures now expands its already impressive investor roster and establishes itself as one of Europe’s largest early stage life sciences investment funds.

The Ghent-based life science fund V-Bio Ventures has announced the final closing of its first fund. While the fund was already up and running in November of last year, the team has now further increased its capital to manage a total of €76 million. New participants in the fund include UGent, Gimv, BNP Paribas Fortis Private Equity and federal investment vehicle FPIM/SFPI. They complete the already existing supporters Korys, ARKimedes, KULeuven and the European Investment Fund (EIF).

V-Bio hasn’t been idle in its first year: the fund has invested in three promising young companies. Orionis Biosciences and Confo Therapeutics are two spin-outs from VIB, exemplifying V-Bio’s close relationship with the research institute. UK-based eye specialist Oxular Ltd (formerly Precision Ocular Ltd) was identified as a third opportunity.

Also the fund’s team expanded since last year. Ward Capoen joined from Candrian Investment group while Katja Rosenkranz, originally from Munich and with extensive tech transfer experience, gives the team some international flair. Together with Managing Partners Christina Takke and Willem Broekaert, they form the team of seasoned professionals behind V-Bio Ventures.

Read more
Biotech through the eyes of a financial analyst
Inside a life sciences fund: V-Bio Ventures


 

Read more about: , .

RELATED ARTICLES
Inside a life sciences fund: V-Bio Ventures

V-Bio Ventures, the new Belgian fund for life sciences startups, is currently being managed by Christina Takke and Willem Broekaert. They both hav…


Biotechs and subsidies - a fraught relationship

The ambition of any CEO heading a biotech start-up is to develop a new product and to reach patients quickly. However, drug development comes with…


Biotech through the eyes of a financial analyst

Ward Capoen studied biology and subsequently obtained a PhD in biotechnology at Ghent University. He worked as a postdoctoral fellow at the John I…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Janssen V-Bio Ventures GSK UGent Flanders.bio XpandInnovation KU Leuven Itera Life Science Turnstone Biowin

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.